Skip to main content

Table 1 Cardiac function analysis with echocardiography

From: SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects

Groups

S

B

A

AL

AA

Before AMI

LVEF(%)

70.52±2.09

69.27±2.33

68.75±3.01

70.11±2.67

69.35±2.82

FS(%)

35.98±3.15

34.83±4.02

37.09±3.73

36.62±4.09

35.26±3.35

LVVs(ml)

2.03±0.27

1.99±0.35

2.16±0.31

2.08±0.30

2.05±0.28

LVVd(ml)

5.76±0.30

5.97±0.38

5.85±0.41

5.81±0.34

5.85±0.31

CO(ml)

3.72±0.18

3.98±0.27

3.69±0.22

3.73±0.21

3.81±0.25

HR(bpm)

454±68

462±59

455±61

466±78

459±71

One day after AMI

LVEF(%)

69.51±1.94

46.13±2.61*

45.26±2.44*

46.09±2.72*

45.68±2.59*

FS(%)

35.78±3.23

25.71±3.06*

26.07±2.99*

25.22±3.30*

24.97±3.26*

LVVs(ml)

2.08±0.31

3.52±0.31*

3.47±0.36*

3.56±0.29*

3.45±0.30*

LVVd(ml)

5.82±0.27

6.49±0.37*

6.71±0.35*

6.55±0.42*

6.61±0.39*

CO(ml)

3.74±0.19

2.97±0.22*

3.24±0.27*

2.99±0.24*

3.16±0.25*

HR(bpm)

461±70

536±67

551±56

549±62

541±71

Seven days after AMI

LVEF(%)

70.07±2.11

44.91±2.72*

55.57±3.61*#

49.98±3.03*#$

48.98±2.87*#$

FS(%)

36.09±3.12

23.96±3.41*

32.58±3.35#

27.20±3.27*#$

27.86±3.32*#$

LVVs(ml)

2.04±0.25

3.63±0.37*

2.71±0.53*#

3.11±0.46*#

3.18±0.41*#

LVVd(ml)

5.67±0.23

6.53±0.29*

6.03±0.28*#

6.26±0.24*

6.41±0.26*$

CO(ml)

3.63±0.21

2.90±0.24*

3.32±0.31

3.09±0.26*

3.23±0.29*#$

HR(bpm)

457±63

547±66

488±57

517±68

522±63

  1. · * P<0.05 vs. Sham group.
  2. · # P<0.05 vs. Blank Control group.
  3. · $ P<0.05 vs. Atorvastatin group.
  4. · S=Sham operated group; B=Blank control group; A=Atorvastatin group; AL=Atorvastatin+L-NAME group; AA=Atorvastatin+AMD3100 group.